Scil Technology excels by covering the entire development chain from laboratory, preclinical and clinical development, respecting regulatory guidelines, to create cutting edge biopharmaceuticals.
The company applies its proprietary technology and utilizes an interdisciplinary approach for its product development. Beside injectable formulations of protein based biopharmaceuticals, the portfolio also comprises of growth factor activated devices, where biomaterials like organic and inorganic polymers are used as delivery system for protein drugs. The development of innovative formulations or special delivery systems could potentially lead to novel forms of administration or even new fields of application. Scil Technology increases thus the value not only for new, but also for well known protein based pharmaceuticals.
The special know-how within protein-formulation and analytics is now offerd by Formycon GmbH. www.formycon.com